CA2303591C - Methode et compositions pour prevenir ou reduire l'infection par le vih - Google Patents

Methode et compositions pour prevenir ou reduire l'infection par le vih Download PDF

Info

Publication number
CA2303591C
CA2303591C CA 2303591 CA2303591A CA2303591C CA 2303591 C CA2303591 C CA 2303591C CA 2303591 CA2303591 CA 2303591 CA 2303591 A CA2303591 A CA 2303591A CA 2303591 C CA2303591 C CA 2303591C
Authority
CA
Canada
Prior art keywords
lapase
estrogen
use according
inhibitor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2303591
Other languages
English (en)
Other versions
CA2303591A1 (fr
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Original Assignee
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/fr
Application filed by Canbreal Therodiagnostics Canada Holding Corp, Canada Minister of Health filed Critical Canbreal Therodiagnostics Canada Holding Corp
Priority to CA 2303591 priority Critical patent/CA2303591C/fr
Publication of CA2303591A1 publication Critical patent/CA2303591A1/fr
Application granted granted Critical
Publication of CA2303591C publication Critical patent/CA2303591C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2303591 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih Expired - Fee Related CA2303591C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303591 CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,267,481 1999-03-30
CA002267481A CA2267481A1 (fr) 1999-03-30 1999-03-30 Interdependance critique : du role de l'oestrogene dans le cancer du sein a la sensibilite des femmes a l'infection par le vih
CA 2303591 CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Publications (2)

Publication Number Publication Date
CA2303591A1 CA2303591A1 (fr) 2000-09-11
CA2303591C true CA2303591C (fr) 2002-12-17

Family

ID=25680865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303591 Expired - Fee Related CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Country Status (1)

Country Link
CA (1) CA2303591C (fr)

Also Published As

Publication number Publication date
CA2303591A1 (fr) 2000-09-11

Similar Documents

Publication Publication Date Title
US6406701B1 (en) Method and compositions for preventing or reducing HIV infection
KR100667121B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
EP0822941B1 (fr) Anticorps monoclonaux contre vih 1 et vaccins en decoulant
US6177253B1 (en) Screening methods for the identification of anti-HIV compounds employing a cyclosporine-specific monoclonal antibody that cross-reacts with HIV-1 p24
JPH06502539A (ja) Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
US6140043A (en) Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the IFN-receptor and means for diagnosis of an HIV infection
Edson et al. Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus
JP2888980B2 (ja) Ｈｉｖ免疫療法
CN110612120A (zh) 使用特异性于α4β7整联蛋白的抗体(维多珠单抗)治疗儿科病症的方法
US6241986B1 (en) Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV
US6268484B1 (en) HIV-vaccines
Onyekaba et al. Persistent infection of mice by lactate dehydrogenase-elevating virus: effects of immunosuppression on virus replication and antiviral immune responses
Stein et al. Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual
US5981278A (en) Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6200575B1 (en) Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
EP2697259B1 (fr) Compositions destinées au traitement prophylactique et/ou thérapeutique d'une infection par un virus vih-1
CA2303591C (fr) Methode et compositions pour prevenir ou reduire l'infection par le vih
US5567805A (en) The cellular receptor for the CS3 peptide of human immunodeficiency virus
EP0379295A2 (fr) Anticorps antitryptase et composition pour le traitement du sida utilisant cet anticorps
JP4310498B2 (ja) ＨＩＶ感染細胞にアポトーシスを誘導するヒトＩｇＭ抗体及びＨＩＶ感染症治療剤
EP4070814A1 (fr) Polypeptides sars-cov-2 et leurs utilisations
US5529776A (en) Anti-HIV-1 neutralizing antibodies
WO1993020104A9 (fr) Anticorps monoclonaux agissant contre un determinant antigenique dependant de glucides correspondant a la region v2 de gp120 de hiv-1
WO1993020104A1 (fr) Anticorps monoclonaux agissant contre un determinant antigenique dependant de glucides correspondant a la region v2 de gp120 de hiv-1

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130402